Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0843
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma ; volume:89 ; number:2 ; day:3 ; month:1 ; year:2022 ; pages:151-164 ; date:2.2022
Cancer chemotherapy and pharmacology ; 89, Heft 2 (3.1.2022), 151-164, 2.2022
- Creator
-
Dosne, Anne-Gaëlle
Valade, Elodie
Goeyvaerts, Nele
De Porre, Peter
Avadhani, Anjali
O’Hagan, Anne
Li, Lilian Y.
Ouellet, Daniele
Perez Ruixo, Juan Jose
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00280-021-04381-4
- URN
-
urn:nbn:de:101:1-2022051020590378057245
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dosne, Anne-Gaëlle
- Valade, Elodie
- Goeyvaerts, Nele
- De Porre, Peter
- Avadhani, Anjali
- O’Hagan, Anne
- Li, Lilian Y.
- Ouellet, Daniele
- Perez Ruixo, Juan Jose
- SpringerLink (Online service)
Other Objects (12)
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding
Management of Locally Advanced Unresectable or Metastatic Urothelial Carcinoma: Expert Opinion from an Indian Panel via Delphi Consensus Method
A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
Recent advances in medical therapy for metastatic urothelial cancer
Enhanced metastatic potential in the MB49 urothelial carcinoma model
Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
Programmed cell death 1 inhibitor alone or combined with chemotherapy for patients with locally advanced or metastatic urothelial carcinoma: a single-center experience
HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study
Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding
Management of Locally Advanced Unresectable or Metastatic Urothelial Carcinoma: Expert Opinion from an Indian Panel via Delphi Consensus Method
A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
Recent advances in medical therapy for metastatic urothelial cancer
Enhanced metastatic potential in the MB49 urothelial carcinoma model
Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
Programmed cell death 1 inhibitor alone or combined with chemotherapy for patients with locally advanced or metastatic urothelial carcinoma: a single-center experience
HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study
Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding
Management of Locally Advanced Unresectable or Metastatic Urothelial Carcinoma: Expert Opinion from an Indian Panel via Delphi Consensus Method
A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
Recent advances in medical therapy for metastatic urothelial cancer
Enhanced metastatic potential in the MB49 urothelial carcinoma model
Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
Programmed cell death 1 inhibitor alone or combined with chemotherapy for patients with locally advanced or metastatic urothelial carcinoma: a single-center experience
HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study